Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APX 3330

Next Previous
Drug Profile

APX 3330

Alternative Names: APX-3330; E-3330

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Apexian Pharmaceuticals; Ocuphire Pharma
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Neuroprotectants; Quinones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; APEX1 protein inhibitors; DNA apurinic apyrimidinic site lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Hepatitis B; Hepatitis C; Liver cirrhosis
  • Phase I Solid tumours
  • Preclinical Inflammatory bowel diseases; Pancreatic cancer
  • Discontinued Haematological malignancies; Liver disorders; Peripheral nervous system diseases

Most Recent Events

  • 16 Apr 2024 Discontinued - Phase-I for Peripheral nervous system diseases (Chemotherapy-induced) in USA (PO) before April 2024 (Apexian Pharmaceuticals pipeline, April 2024)
  • 29 Feb 2024 Ocuphire Pharma files special protocol assessment (SPA) to US FDA for phase-III trial for Diabetic retinopathy
  • 02 Nov 2023 Ocuphire Pharma announces successful End-of-Phase II Meeting with US FDA for APX 3330 in Diabetic Retinopathy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top